← All trials
NCT02008773
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2014
- Primary completion
- Jun 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 175
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Indiana UniversityLead sponsor
- Indiana UniversityOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- Sheppard Pratt Health SystemOverall official - principal investigator
- Centers for Behavioral Health, LLCOverall official - principal investigator
- Laureate Institute for Brain ResearchOverall official - principal investigator
- Innovative Clinical Research, Inc.Overall official - principal investigator
- University of California, RiversideOverall official - principal investigator
- University of KansasOverall official - principal investigator
- Stanley Medical Research InstituteCollaborator
- Sheppard Pratt Health SystemCollaborator
- University of MarylandCollaborator
- University of California, Los AngelesCollaborator
- Yale UniversityCollaborator
- Centers for Behavioral Health, LLCCollaborator
- Innovative Clinical Research, Inc.Collaborator
- Indiana UniversityReponsible party - principal investigator
- University of KansasCollaborator
- Laureate Institute for Brain ResearchCollaborator
- University of California, RiversideCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.